Generic name · Chemotherapy / VEGF Biologic
Bevacizumab J-Code / HCPCS Code
In short
Bevacizumab is billed under HCPCS J9035 — Injection, bevacizumab, 10 mg. One billing unit is 10 mg.
Bevacizumab biosimilars have their own HCPCS codes.
Reference
- Code
- J9035 — Injection, bevacizumab, 10 mgMed-Code curated
- Billing unit
- 10 mg
- Same code in the directory
- Avastin
- Pharmacologic class
- Vascular Endothelial Growth Factor InhibitorFrom the FDA listings below
- Labelers
- Amgen, Inc; Amneal Pharmaceuticals LLC; Biocon Biologics Inc.; CELLTRION USA, Inc.; Genentech, Inc.; Outlook Therapeutics, Inc.; Pfizer Laboratories Div Pfizer Inc; Valorum Biologics, LLC
- J-code category
- Chemotherapy / VEGF Biologic
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Alymsysbevacizumab-maly | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Amneal Pharmaceuticals LLC | 70121-1754 |
| Alymsysbevacizumab-maly | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Amneal Pharmaceuticals LLC | 70121-1755 |
| Avastinbevacizumab | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-060 |
| Avastinbevacizumab | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-061 |
| Mvasibevacizumab-awwb | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Amgen, Inc | 55513-206 |
| Mvasibevacizumab-awwb | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Amgen, Inc | 55513-207 |
| Vegzelmabevacizumab-adcd | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | CELLTRION USA, Inc. | 72606-011 |
| Vegzelmabevacizumab-adcd | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | CELLTRION USA, Inc. | 72606-012 |
| Zirabevbevacizumab-bvzr | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | Pfizer Laboratories Div Pfizer Inc | 0069-0315 |
| Zirabevbevacizumab-bvzr | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | Pfizer Laboratories Div Pfizer Inc | 0069-0342 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Alymsysbevacizumab-maly | Bevacizumab-maly 100 mg/4mL | Injection, SolutionIntravenous | Valorum Biologics, LLC | 85006-1754 |
| Alymsysbevacizumab-maly | Bevacizumab-maly 400 mg/16mL | Injection, SolutionIntravenous | Valorum Biologics, LLC | 85006-1755 |
| Jobevnebevacizumab-nwgd | Bevacizumab 25 mg/mL | InjectionIntravascular | Biocon Biologics Inc. | 83257-009 |
| Jobevnebevacizumab-nwgd | Bevacizumab 25 mg/mL | InjectionIntravascular | Biocon Biologics Inc. | 83257-010 |
| Lytenavabevacizumab-vikg | Bevacizumab 1.25 mg/1 | InjectionIntravitreal | Outlook Therapeutics, Inc. | 82491-025 |
NDCs billed under J9035
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J9035 for Avastin. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Avastin | 50242-0060-01 | Genentech, Inc. | 4 | 10 |
| Avastin | 50242-0061-01 | Genentech, Inc. | 16 | 40 |